PT2049113E - Medicamento para melhoria da função cognitiva e neuroprotecção - Google Patents
Medicamento para melhoria da função cognitiva e neuroprotecção Download PDFInfo
- Publication number
- PT2049113E PT2049113E PT07766491T PT07766491T PT2049113E PT 2049113 E PT2049113 E PT 2049113E PT 07766491 T PT07766491 T PT 07766491T PT 07766491 T PT07766491 T PT 07766491T PT 2049113 E PT2049113 E PT 2049113E
- Authority
- PT
- Portugal
- Prior art keywords
- pyridazinone
- benz
- fluoro
- chloro
- piperidin
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 230000003920 cognitive function Effects 0.000 title claims abstract description 6
- 230000004112 neuroprotection Effects 0.000 title claims description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 208000000044 Amnesia Diseases 0.000 claims abstract description 8
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 5
- 230000016273 neuron death Effects 0.000 claims abstract description 5
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 4
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims abstract description 4
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000003340 mental effect Effects 0.000 claims abstract description 4
- 230000000324 neuroprotective effect Effects 0.000 claims abstract description 3
- 208000031091 Amnestic disease Diseases 0.000 claims abstract 3
- 208000006011 Stroke Diseases 0.000 claims abstract 3
- 230000006986 amnesia Effects 0.000 claims abstract 3
- 230000007423 decrease Effects 0.000 claims abstract 3
- 206010027175 memory impairment Diseases 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- 230000006993 memory improvement Effects 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 2
- 230000015654 memory Effects 0.000 claims description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 4
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 4
- 208000026139 Memory disease Diseases 0.000 claims 4
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 4
- 229960001534 risperidone Drugs 0.000 claims 4
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 4
- 229960002646 scopolamine Drugs 0.000 claims 4
- -1 isoxazole-3-yl Chemical group 0.000 claims 3
- 230000006984 memory degeneration Effects 0.000 claims 3
- 208000023060 memory loss Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims 1
- 230000006386 memory function Effects 0.000 claims 1
- 238000010172 mouse model Methods 0.000 claims 1
- 238000003359 percent control normalization Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000003936 working memory Effects 0.000 claims 1
- 231100000863 loss of memory Toxicity 0.000 abstract description 2
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000007787 long-term memory Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
ΕΡ 2 049 113/ΡΤ
DESCRIÇÃO "Medicamento para melhoria da função cognitiva e neuroprotecção"
Campo da invenção A presente invenção refere-se à utilização de 4-cloro-5-{2 - [4-(6-fluoro-l,2-benz[d]isoxazole-3-il)piperidin-l-il]-etilamino}-2-metil-3-(2H)piridazinona da Fórmula (I)
HN
O e de seus sais farmaceuticamente aceitáveis na preparação de medicamentos para a melhoria da função cognitiva ou obtenção de um efeito neuroprotector, e aos correspondentes métodos de tratamento.
Antecedentes técnicos A 4-cloro-5-{2-[4-(6-fluoro-l,2-benz[d]isoxazole-3-il)-piperidina-l-il]etilamino}-2-meti1-3-(2H)piridazinona da Fórmula (I) e os seus sais farmaceuticamente aceitáveis foram revelados pela primeira vez no Pedido Internacional de Patente N.° WO 03/010166 e no Pedido Húngaro de Patente N.° P0103063. O pedido WO 03042212 revela compostos similares, com uma pirimidina no lugar de uma pirimidina, para o tratamento de distúrbios dependentes da serotonina.
Com base nos conhecimentos disponíveis, sabe-se que a 4-cloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxazole-3-il)piperidina- 2 ΕΡ 2 049 113/ΡΤ 1—i 1 ] etilamino}-2-metil-3-(2H) piridazinona da Fórmula (I) é um potencial fármaco com um valioso efeito neuroléptico, útil no tratamento de psicoses, especialmente a esquizofrenia. A expressão "efeito neuroléptico" é entendida, de acordo com o estado da arte, como o efeito mitigador do fármaco antipsicótico em relação ao embaraço, delírios, alucinações e excitação psicomotora, resultantes de psicoses em paciente que sofrem destas doenças.
Nas últimas décadas, têm surgido várias doenças no domínio de interesse da investigação medicinal que estão associadas a morte neuronal, decadência neuronal crónica, diminuição das capacidades mentais ou demência resultantes do progresso de envelhecimento.
Esses distúrbios incluem esclerose múltipla, doença de Creuzfeld-Jacob, doença de Huntington, esclerose lateral amiotrófica (ELA), doença de Parkinson, acidente vascular cerebral e morte neuronal devido a traumas agudos cerebrais ou da medula espinal, ou resultantes da exposição a substâncias tóxicas, ou como consequência de isquemia. Os sintomas característicos dos distúrbios atrás mencionados são a diminuição na capacidade de aprendizagem, perda de memória e, em alguns casos, declínio da capacidade mental.
Com base no estado da técnica, há dois tipos de memória. A chamada "memória de curto prazo", que caracteriza a retenção de informações para um curto intervalo de tempo alguns minutos e algumas horas. A expressão "memória de longo prazo" refere-se à retenção de informações para períodos que variam entre horas e anos (Baddley and Warington, J. Verb. Learn. Verb. Behav. 9, 176-179 [1970]); Wright et ai., Science 229, 287-289 [1985]). 0 processo de transferência de informações da memória de curto prazo para a memória de longo prazo é denominado consolidação. 0 processo de trazer de volta as informações tanto da memória de curto prazo como da memória de longo prazo é denominado retenção.
Claims (5)
- ΕΡ 2 049 113/PT 1/1 REIVINDICAÇÕES 1. Utilização de 4-cloro-5-{2-[4-(6-fluoro-1,2-benz[d]-isoxazole-3-il)piperidin-l-il]etilamino}-2-meti1-3-(2H) -piridazinona da Fórmula (I)ou de um seu sal farmaceuticamente aceitável, para o fabrico de um medicamento para a prevenção ou tratamento de morte neuronal, declínio mental, esclerose múltipla, doença de Creutzfeldt-Jakobs, doença de Huntington, esclerose lateral amiotrófica, doença de Parkinson ou acidente vascular cerebral.
- 2. Utilização de 4-cloro-5-{2-[4-(6-fluoro-1,2-benz[d]-isoxazole-3-il)piperidin-l-il]etilamino}-2-meti1-3-(2H)-piridazinona da Fórmula (I) ou de um sal farmaceuticamente aceitável para o fabrico de um medicamento para melhoria da capacidade de aprendizagem ou reforço da memória.
- 3. Utilização de 4-cloro-5-{2-[4-(6-fluoro-1,2-benz[d]- isoxazole-3-il)piperidid-l-il]etilamino}-2-meti1-3-(2H)-piridazinona da Fórmula (I) ou de um seu sal farmaceuticamente aceitável para o fabrico de um medicamento para melhoria da memória ou tratamento ou prevenção de perda de memória, perturbação da memória ou amnésia.
- 4. Utilização de 4-cloro-5-{2-[4-(6-fluoro-1,2-benz[d]- isoxazole-3-il)piperidin-l-il]etilamino}-2-meti1-3-(2H)-piridazinona da Fórmula (I) ou de um seu sal farmaceuticamente aceitável para o fabrico de um medicamento para melhoria da capacidade de aprendizagem. Lisboa, 2010-08-19 ΕΡ 2 049 113/ΡΤ RESUMO "Medicamento para melhoria da função cognitiva e neuroprotecção" A presente invenção refere-se à utilização de 4-cloro-5-{2-[4-(6—fluoro-1,2-benz[d]isoxazole-3-il)piperidina-l-il]-etilamino}-2-metil-3-(2H)piridazinona da Fórmula (I), ou de seus sais farmaceuticamente aceitáveis, na preparação de medicamentos adequados para a melhoria da função cognitiva ou obtenção de um efeito neuroprotector. Os medicamentos contendo 4-cloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxazole-3-il)piperidin-1-il]etilamino}-2-metil-3-(2H)piridazinona da Fórmula (I) ou um seu sal terapeuticamente aceitável podem ser usados no tratamento ou prevenção de morte neuronal, declínio mental, esclerose múltipla, doença de Creutzfeldt-Jakobs, doença de Huntington, esclerose lateral amiotrófica, doença de Parkinson, perturbação da memória, perda de memória, amnésia, acidente vascular cerebral, ou para melhoria da função de memória ou da capacidade de aprendizagem. ΕΡ 2 049 113/ΡΤ 1/6 Figura 1 Efeitos de 4-cloro-5-(2-[4-(6-fluoro-1,2-benz[d]-isoxazole-3-il)-piperidin-1-il]etil-amino)-2-metil-3-(2H)-piridazinona (T) e de risperidona (R) no modelo murino de isquemia focal permanente 4-c[oro-5-(2-[4-(6-fluoro-1,2-benz[d]isoxazole-3-il)-piperidin-1-il]etilamino)-2-met il-3-(2H)piridazinona (T) 100 90 SO S & 70 n 60 O L. <u O 50 £ k £ 40 c Φ 30 o Φ 20 ε 3 O 10 > 0 100 90 80 E E w 70 ffi Δ 60 4) 4) O 50 £ t. •S 40 c φ 30 8 φ ε 20 3 Õ 10 > 0 0%Controlo 0.01 0.03 mg/kg i.p.0.3 mg/kg i.p. Controlo 0.1 ΕΡ 2 049 113/ΡΤ 2/6 Figura 1 (cont.) Risperidona (R) "e E £ c 0> o u Φ E 3 O >Controlo 0.01 0.03 mg/kg i.p. "a E c 0» <u E o >Controlo 03 mg/kg i.p. 0.1 EP 2 049 113/PT 3/6 Figura 2 Efeitos de 4-cloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxa-zole-3-il)-piperidin-1-il]etilamino}-2-metil-3-(2H)piridazi-nona (teste) e de risperidona (risp) no modelo de rejeição passiva Latência no dia 2 <s) Latência no dia 2 <s>Controlo 0,4 mA/1 Os ch. + teste 0,005teste 0,005 Tratamento mg/kg p.o.Controlo ch. + risp 0,005 0,4 mA/1 Os risp 0,5 Tratamento mg/kg p.o. EP 2 049 113/PT 4/6 Figura 3 Efeito da 4-cloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxa-zole-3-il)piperidin-1-il]etilamino}-2-metil-3-(2H)piridazi-nona (teste) no défice de memória induzido por escopolamina no teste do labirinto de 8 braços Respostas iniciais correctas Número de respostas iniciais correctasEP 2 049 113/PT 5/6 Erros da memória de trabalho Número de erros Número de erros** controlo + vs escopolamína ±Erro padrão Média Numero total de erros 12 10 e 6 4 2 0 ** *♦** controlo ' + vs escopolamína Controlo escopolamína risperidona composto de teste ±Erro padrão Média ΕΡ 2 049 113/PT 6/6 Figura 4 Efeito da 4-cloro-5-{2-[4-(6-fluoro-1,2-benz[d]isoxazol-3-il)-piperidin-1-il]etilamino}-2-metil-3-(2H)piridazinona no modelo de reconhecimento de objectos (composto de teste) O O* «3 C to- O (fl Φ Ό Φ O
- 5- C 0mssel 1. diaComposto de teste Controlo (0,01 mg/kg p.o.) p<0,05 comparado ao controlo
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0600555A HUP0600555A3 (en) | 2006-07-03 | 2006-07-03 | Use of 4-chloro-5-{2-[4-(6-fluoro-1,2-benz[d]izoxazol-3-yl)piperidin-1-yl]ethylamino}2-methyl-3(2h)-piridazinon for the production of pharmaceutical compositions for influencing cognitive functions and causing neuroprotective effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2049113E true PT2049113E (pt) | 2010-08-26 |
Family
ID=89986887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT07766491T PT2049113E (pt) | 2006-07-03 | 2007-07-03 | Medicamento para melhoria da função cognitiva e neuroprotecção |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8318743B2 (pt) |
| EP (1) | EP2049113B8 (pt) |
| JP (1) | JP5174018B2 (pt) |
| KR (1) | KR101465415B1 (pt) |
| CN (1) | CN101516373B (pt) |
| AT (1) | ATE468854T1 (pt) |
| AU (1) | AU2007270910B2 (pt) |
| BR (1) | BRPI0713395A2 (pt) |
| CA (1) | CA2656549C (pt) |
| CY (1) | CY1110741T1 (pt) |
| DE (1) | DE602007006813D1 (pt) |
| DK (1) | DK2049113T3 (pt) |
| EA (1) | EA016142B1 (pt) |
| HK (1) | HK1131032A1 (pt) |
| HR (1) | HRP20100465T1 (pt) |
| HU (1) | HUP0600555A3 (pt) |
| IL (1) | IL196315A (pt) |
| MA (1) | MA30951B1 (pt) |
| MX (1) | MX2009000243A (pt) |
| NZ (1) | NZ574596A (pt) |
| PL (1) | PL2049113T3 (pt) |
| PT (1) | PT2049113E (pt) |
| RS (1) | RS51429B (pt) |
| SI (1) | SI2049113T1 (pt) |
| WO (1) | WO2008004013A2 (pt) |
| ZA (1) | ZA200900507B (pt) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9602763A3 (en) | 1996-10-09 | 1999-05-28 | Egyt Gyogyszervegyeszeti Gyar | 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same |
| WO2001017993A1 (en) | 1999-09-09 | 2001-03-15 | EGIS Gyógyszergyár Rt. | Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient |
| HU225955B1 (en) * | 2001-07-26 | 2008-01-28 | Egis Gyogyszergyar Nyilvanosan | Novel 2h-pyridazin-3-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them |
| US20030024849A1 (en) * | 2001-07-26 | 2003-02-06 | Nielsen Jacob Sturich | Package for blister pack strips |
| HU227118B1 (en) * | 2001-11-13 | 2010-07-28 | Egis Gyogyszergyar Nyilvanosan | Process for the preparation of 3-{2-[4-(6-fluoro-1,2-benzizoxazol-3-yl)-1-piperidinyl]-ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one |
| HU227255B1 (en) * | 2002-04-26 | 2010-12-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Novel piperidine-alkyl-amino-pyridazine derivatives, pharmaceutical compositions containing the same and process for the preparation of the active ingredient |
-
2006
- 2006-07-03 HU HU0600555A patent/HUP0600555A3/hu unknown
-
2007
- 2007-07-03 RS RSP-2010/0375A patent/RS51429B/en unknown
- 2007-07-03 MX MX2009000243A patent/MX2009000243A/es active IP Right Grant
- 2007-07-03 EP EP07766491A patent/EP2049113B8/en active Active
- 2007-07-03 ZA ZA200900507A patent/ZA200900507B/xx unknown
- 2007-07-03 US US12/307,385 patent/US8318743B2/en not_active Expired - Fee Related
- 2007-07-03 WO PCT/HU2007/000059 patent/WO2008004013A2/en active Application Filing
- 2007-07-03 DE DE602007006813T patent/DE602007006813D1/de active Active
- 2007-07-03 EA EA200900088A patent/EA016142B1/ru not_active IP Right Cessation
- 2007-07-03 CN CN2007800306551A patent/CN101516373B/zh not_active Expired - Fee Related
- 2007-07-03 CA CA2656549A patent/CA2656549C/en not_active Expired - Fee Related
- 2007-07-03 DK DK07766491.0T patent/DK2049113T3/da active
- 2007-07-03 NZ NZ574596A patent/NZ574596A/xx not_active IP Right Cessation
- 2007-07-03 AU AU2007270910A patent/AU2007270910B2/en not_active Ceased
- 2007-07-03 PL PL07766491T patent/PL2049113T3/pl unknown
- 2007-07-03 KR KR1020097002214A patent/KR101465415B1/ko not_active IP Right Cessation
- 2007-07-03 SI SI200730327T patent/SI2049113T1/sl unknown
- 2007-07-03 AT AT07766491T patent/ATE468854T1/de active
- 2007-07-03 BR BRPI0713395-2A patent/BRPI0713395A2/pt not_active IP Right Cessation
- 2007-07-03 JP JP2009517450A patent/JP5174018B2/ja not_active Expired - Fee Related
- 2007-07-03 PT PT07766491T patent/PT2049113E/pt unknown
-
2009
- 2009-01-01 IL IL196315A patent/IL196315A/en not_active IP Right Cessation
- 2009-01-27 MA MA31589A patent/MA30951B1/fr unknown
- 2009-09-11 HK HK09108358.0A patent/HK1131032A1/xx not_active IP Right Cessation
-
2010
- 2010-08-18 CY CY20101100766T patent/CY1110741T1/el unknown
- 2010-08-23 HR HR20100465T patent/HRP20100465T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2592075B1 (en) | Pyridazine compounds for the treatment of inflammatory diseases | |
| US9782398B2 (en) | Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof | |
| Stahlmann et al. | Fluoroquinolones in the elderly: safety considerations | |
| BR112013019643B1 (pt) | Uso de inibidores de álcali | |
| CA2650711A1 (en) | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | |
| WO2009017836A1 (en) | Methods and compositions for treating schizophrenia using antipsychotic combination therapy | |
| TW201306840A (zh) | 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌□反其鹽用於治療精神分裂症的方法 | |
| CN104662007A (zh) | 胱硫醚-γ-裂合酶(CSE)抑制剂 | |
| MX2008013843A (es) | Formulaciones que contienen compuestos de piridazina para tratar enfermedades neuroinflamatorias. | |
| BRPI0616659A2 (pt) | droga terapÊutica antituberculose, medicamento, e, kit para o tratamento de tuberculose | |
| PT1621198E (pt) | Derivados de carboestirilo substituídos como agonistas do subtipo 1a de receptores 5-ht | |
| CA2589102C (en) | Pyridazine compounds and methods for using the compounds to treat inflammatory diseases | |
| TW201211022A (en) | Methods of use of cyclic amide derivatives to treat sigma receptor-mediated disorders | |
| WO2015129527A1 (ja) | プラミペキソールを含有する神経変性疾患の治療用貼付剤 | |
| AU2021363627A1 (en) | Use of benzodiazepines to increase sensitivity to psilocybin following a chronic SSRI regimen | |
| KR102023748B1 (ko) | 순수한 5-ht6 수용체 길항제 및 nmda 수용체 길항제의 조합물 | |
| PT2049113E (pt) | Medicamento para melhoria da função cognitiva e neuroprotecção | |
| AU2016220049C1 (en) | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau | |
| JPH03170428A (ja) | 精神疾患治療剤 | |
| RU2508106C2 (ru) | Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии | |
| Takahama et al. | Anaphylaxis due to levofloxacin. | |
| BR112020013697A2 (pt) | compostos para tratamento de sintomas negativos e comprometimentos cognitivos | |
| TW201035081A (en) | Novel pharmaceutical composition for treatment of schizophrenia | |
| RU2508096C2 (ru) | Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии | |
| TW200911247A (en) | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament for use in the treatment of motor disorders related to parkinson's disease |